普蕊斯（301257）公告，公司实际控制人、董事长赖春宝先生的增持计划已实施完成。自2025年1月15 日至2025年6月10日期间，赖春宝先生通过深圳证券交易所交易系统以集中竞价方式累计增持公司股份 22.48万股，占公司总股本的0.28%，增持金额为674.25万元(不含交易费用)。本次股份增持计划已实施 完毕。 ...

北京国枫律师事务所 关于普蕊斯（上海）医药科技开发股份有限公司 实际控制人增持公司股份的 法律意见书 国枫律证字[2025]AN085-1 号 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层 邮编：100005 电话（Tel）：010-88004488/66090088 传真（Fax）：010-66090016 释 义 注：本法律意见书中若存在总数合计与各分项数值之和尾数不符的，系由四舍五入原因所致。 1 本法律意见书中，除非文义另有所指，下列词语或简称具有如下含义： 普蕊斯、公司 指 普蕊斯（上海）医药科技开发股份有限公司 增持人 指 赖春宝，系普蕊斯实际控制人 本次增持 指 增持人于 2025 年 1 月 15 日至 2025 年 6 月 10 日期间通过集中竞 价方式增持普蕊斯股份事宜 《公司法》 指 《中华人民共和国公司法》 《证券法》 指 《中华人民共和国证券法》 《收购管理办法》 指 《上市公司收购管理办法》 《自律监管指引第 10 号》 指 《深圳证券交易所上市公司自律监管指引第 10 号——股份变动 管理》 证监会 指 中国证券 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-036 普蕊斯（上海）医药科技开发股份有限公司 关于实际控制人增持股份计划实施完成的公告 公司实际控制人赖春宝先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 1、增持计划的基本情况：普蕊斯（上海）医药科技开发股份有限公司（以 下简称"公司"）于 2025 年 1 月 14 日披露《关于实际控制人增持股份计划的公 告》（公告编号：2025-002），公司实际控制人、董事长赖春宝先生计划自本次 增持计划公告发布之日起 6 个月内，通过包括但不限于集中竞价、大宗交易等方 式增持公司股份，增持计划金额不低于人民币 600 万元且不超过人民币 900 万元 （均含本数，下同）。 2、增持计划的进展情况：截至本公告披露日，赖春宝先生的增持计划已实 施完成。自 2025 年 1 月 15 日至 2025 年 6 月 10 日期间，赖春宝先生通过深圳证 券交易所交易系统以集中竞价方式累计增持公司股份 224,800 股，占公司总股本 的 0.2 ...

Investment Rating - Investment Rating: Positive [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 3.36%, ranking 6th among 31 primary industries, outperforming the CSI 300 index, which decreased by 0.21% [5][17] - The valuation of the pharmaceutical and biotechnology industry as of June 6, 2025, is 28.24x (TTM, excluding negative values), up from 27.60x in the previous period, indicating an upward trend but still below the average [5][23] - Notable sub-industry performance includes chemical preparations and other biological products, with increases of 5.77% and 4.68% respectively, while offline pharmacies saw a decline of 1.15% [5][17] Industry Review - The report highlights three major investment opportunities: 1) Companies with dual-antibody/multi-antibody technology platforms that have differentiated target design capabilities and clinical advancement efficiency are likely to attract international giants [9] 2) Areas with unmet clinical needs, such as advanced liver cancer and non-small cell lung cancer, are promising for dual-antibody therapy development [9] 3) Potential license-out candidates, as domestic innovative pharmaceutical companies continue to engage in global collaborations [9] Important Industry News - CDE launched the "Star Plan" to encourage the development of pediatric anti-cancer drugs, addressing significant unmet clinical needs in this area [7][32] - Alcon's dry eye medication "Tryptyr" received FDA approval, marking it as the first of its kind globally [39] - Hansoh Pharmaceutical's third-generation EGFR-TKI "Amivantamab" was approved in the UK for first-line treatment of NSCLC, becoming the first domestically developed EGFR-TKI approved overseas [42] - BMS and BioNTech entered a collaboration for the dual-antibody candidate BNT327, with an upfront payment of $1.5 billion and potential milestone payments of $7.6 billion [51] Company Dynamics - Stone Pharmaceutical is negotiating three potential deals totaling $5 billion, involving several products including EGFR ADCs [49] - BMS's "Rotecip" was approved for treating lower-risk myelodysplastic syndromes, marking a significant innovation in this therapeutic area [45] - AbbVie’s JAK inhibitor "Upadacitinib" was approved for treating giant cell arteritis, becoming the first approved treatment for this condition in China [48]

Group 1 - The hepatitis concept sector declined by 1.36%, ranking among the top declines in concept sectors, with major declines seen in companies like Hai Chen Pharmaceutical, Hainan Hai Pharmaceutical, and Nuotai Biological [1][2] - Among the 18 stocks that rose, Fu Rui Co., Ltd., Fozi Pharmaceutical, and *ST Shuangcheng led with increases of 6.42%, 5.79%, and 5.03% respectively [1][2] - The hepatitis concept sector experienced a net outflow of 859 million yuan from main funds, with 88 stocks seeing net outflows, and five stocks exceeding 50 million yuan in outflows [2][6] Group 2 - Hai Chen Pharmaceutical had the highest net outflow of main funds at 119 million yuan, followed by Zhongsheng Pharmaceutical, Nuotai Biological, and Lu Kang Pharmaceutical with outflows of 95.25 million yuan, 92.01 million yuan, and 88.21 million yuan respectively [2][6] - The stocks with the highest net inflows included Fu Rui Co., Ltd., Zhongheng Group, and Te Bao Biological, with inflows of 52.72 million yuan, 39.98 million yuan, and 37.06 million yuan respectively [2][6]

Market Overview - The Shanghai Composite Index closed at 3348.37 points, above the annual line, with a decline of 0.94% [1] - The total trading volume of A-shares reached 1,182.564 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including: - Pruis (4.48% deviation) - Yingjie Electric (3.80% deviation) - Boying Special Welding (3.01% deviation) [1] - Stocks with smaller deviations just above the annual line include: - Shuangjian Co., Ltd. - Rhine Biology - Bull Group [1] Top Performers - The top three stocks with the highest deviation rates from the annual line are: 1. Pruis: 5.17% increase, 8.64% turnover rate, latest price 30.12 yuan 2. Yingjie Electric: 5.80% increase, 8.35% turnover rate, latest price 48.50 yuan 3. Boying Special Welding: 3.28% increase, 6.03% turnover rate, latest price 22.70 yuan [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Fosa Technology: 3.03% increase, 8.32% turnover rate, latest price 32.31 yuan - Shandong Haihua: 5.57% increase, 6.80% turnover rate, latest price 5.88 yuan - Renfu Pharmaceutical: 3.06% increase, 2.53% turnover rate, latest price 20.88 yuan [1]

Market Overview - As of 13:59 today, the Shanghai Composite Index is at 3372.33 points, with a slight decline of -0.23% [1] - The total trading volume of A-shares today is 838.849 billion yuan [1] Stocks Breaking Annual Line - A total of 68 A-shares have surpassed their annual line today, with notable stocks including: - Puris (乖离率 6.48%) - Aisen Co., Ltd. (乖离率 5.81%) - Fosa Technology (乖离率 4.02%) [1] Stocks with Significant Deviation - The stocks with the largest deviation from the annual line include: - Puris: Today's price increased by 7.19% to 30.70 yuan - Aisen Co., Ltd.: Today's price increased by 7.47% to 42.00 yuan - Fosa Technology: Today's price increased by 4.30% to 32.71 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance and their respective deviations include: - Yao Stone Technology: 3.77% increase, 3.51% deviation - Fuling Power: 6.24% increase, 3.42% deviation - Yingjie Electric: 5.37% increase, 3.38% deviation [1] Summary of Stocks with Minor Deviations - Stocks with minor deviations from the annual line include: - Huayang Intelligent: 4.58% increase, 2.48% deviation - Boying Special Welding: 2.32% increase, 2.06% deviation - Stone Technology: 2.02% increase, 1.96% deviation [1]

Group 1 - The core viewpoint is that the domestic innovative drug industry is expected to enter a critical turning point by 2025, transitioning from capital-driven to profit-driven, with expectations of valuation recovery and performance realization [1] - The innovative drug sector is anticipated to enter a "results realization phase" by 2025, with prior R&D investments converting into commercial products, significantly improving corporate profitability [1] - The market focus is shifting from financial reports to changes in industry fundamentals, with innovative drugs, overseas expansion, and the impact of centralized procurement becoming core areas of investment attention [1] Group 2 - Prusis, as a leading clinical trial site management organization (SMO) in China, has demonstrated industry recovery trends, with a total of 3,800 SMO projects undertaken and 2,250 projects executed as of the end of Q1 2025, showing a continued increase from 2,161 projects at the end of 2024 [1] - The company reported rapid growth in inquiry volume and new orders in Q1 2025, indicating a preliminary recovery in industry and client demand [2] - The innovative drug sector is undergoing dual validation of valuation and fundamentals, with leading companies accelerating commercialization, providing support for long-term growth [2]

上海市黄浦区中山东二路 600 号 BFC 外滩金融中心 S2 栋 23 层 电话：021-23122000 传真：021-23122100 邮编：200010 北京国枫（上海）律师事务所 关于普蕊斯（上海）医药科技开发股份有限公司 2024 年年度股东大会的法律意见书 国枫律股字［2025］B0012 号 致：普蕊斯（上海）医药科技开发股份有限公司（以下称"贵公司"或"普蕊斯"） 北京国枫（上海）律师事务所（以下称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2024 年年度股东大会（以下称"本次会议"）。 根据《中华人民共和国公司法》（以下称"《公司法》"）、《中华人民共和国 证券法》（以下称"《证券法》"）、中国证券监督管理委员会发布的《上市公司股 东大会规则》（以下称"《股东大会规则》"）、《律师事务所从事证券法律业务管 理办法》（以下称"《从业办法》"）、《律师事务所证券法律业务执业规则（试行）》 （以下称"《执业规则》"）及《普蕊斯（上海）医药科技开发股份有限公司章程》 （以下称"《公司章程》"）等有关规定，就本次会议的召集与召开程序、召集人资 格、出席会议人员资格、会议表决程序及表决结 ...

证券代码:301257 证券简称:普蕊斯 公告编号:2025-035 普蕊斯（上海）医药科技开发股份有限公司 关于回购注销部分限制性股票减资暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开了第三届董事会第十二次会议和第三届监事会第十二次会议，于 2025 年 5 月 20 日召开了 2024 年年度股东大会，审议通过了《关于回购注销 2022 年限制性股票激励计划部分限制性股票的议案》。 鉴于 2024 年公司层面业绩考核指标未达到 2022 年限制性股票激励计划首 次授予部分第三个解除限售期以及预留授予部分第二个解除限售期设定的业绩 考核目标，根据 2022 年限制性股票激励计划的相关规定以及 2022 年第二次临时 股东大会的授权，公司对上述已获授但尚未解除限售的 49.777 万股限制性股票 予以回购注销，回购注销限制性股票占公司总股本的 0.63%。上述内容详见公司 刊登在巨潮资讯网（http://www.cninfo.com.cn）的《 ...